Revanth Reddy seeks US support for Telangana's trillion-dollar vision; urges for stronger business & cultural ties
HYDERABAD: Chief minister A Revanth Reddy on Friday emphasised the deep-rooted bond between the Telugu people and the United States, calling on Americans to support Telangana's ambitious goal of transforming its economy into a one trillion US dollar economy by 2035 and three trillion dollars by 2047.
Speaking at the US Independence Day celebrations organised at a star hotel in Hyderabad by the US Consul General, Revanth Reddy said, "The friendship and connection between the Telugu people and the United States is profound and enduring. Telugu is now the fastest-growing language in the USA. Hyderabad is home to nearly 200 American companies across IT, pharmaceuticals, defence, manufacturing, and aerospace sectors.
Our students travel to the United States in large numbers as part of their aspiration to become global citizens. We are working to strengthen people-to-people ties and expand America-Telangana business links. My govt is fully committed to the 'Telangana Rising' vision, transforming the state's economy to one trillion US dollars by 2035 and three trillion by 2047. To achieve this, we seek the support of the American people."
He lauded US Consul General in Hyderabad, Jennifer Larson, for acting as a strong bridge between the two cultures and nations, enhancing business ties and deepening the broader India-US relationship. "," he said.
You Can Also Check:
Hyderabad AQI
|
Weather in Hyderabad
|
Bank Holidays in Hyderabad
|
Public Holidays in Hyderabad
Revanth highlighted that the US has led the world through significant positive change, especially as a beacon of democracy and a hub for innovation.
"At the national level, the India-US relationship is a strategic global partnership grounded in shared values. Both nations are committed to strengthening ties through expanding trade, commerce, investment, and promoting democracy and global peace," he added.
"I hope you continue to grow your presence in Hyderabad and bring the best of America to Telangana. The theme of this celebration is 'Together - Stronger', and I truly believe we can grow stronger together," CM said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 minutes ago
- Time of India
Iran Claims Direct Hit On $15 MN U.S. Radar System In Qatar; Al Udeid Base ‘Damaged'
/ Jul 14, 2025, 09:32PM IST Iran has released what it claims is visual proof of a successful missile strike on a key U.S. military communications facility at Al Udeid Airbase in Qatar, the largest American base in the Middle East. A satellite image circulated by PressTV and Iran's embassy in India appears to show visible damage to a $15 million radar system, allegedly hit during Iran's June 23 retaliatory strike following the Iran-Israel conflict. Watch
Mint
17 minutes ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
Time of India
18 minutes ago
- Time of India
‘They don't need…certainly...': Nvidia CEO Jensen Huang on concerns over China military using US chips
Nvidia CEO Jensen Huang has pushed back against US concerns that his company's chips could aid the Chinese military. His comments come as Huang prepares for his second trip to China this year for which he has also been sent a 'warning letter' by some US senators. Speaking in a CNN interview, Huang asserted that the Chinese military "don't need Nvidia's chips, certainly, or American tech stacks in order to build their military,' elaborating, 'they simply can't rely on it' because US technology 'could be limited at any time; not to mention, there's plenty of computing capacity in China already.' These remarks address US policy that restricts advanced artificial intelligence (AI) chip sales to China. Huang has previously criticised these export controls, arguing they are 'counterproductive' to the US's goal of maintaining tech leadership. 'Want American tech stack to be the global standard': Huang He stressed that for the 'American tech stack to be the global standard,' the technology must be accessible to AI developers worldwide, including the 50% located in China. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Milano: AudioNova cerca per un test 700 persone nate prima del 1974 AudioNova Undo The latest US restrictions on Nvidia's sales to China, implemented in April, are projected to result in billions in losses for the company. In May, Huang noted that previous chip restrictions had already cut Nvidia's China market share by nearly half. Nvidia is reportedly developing a new chip that complies with the latest export controls. Last week, the Nvidia CEO met with US President Donald Trump, and lawmakers reportedly cautioned him against engaging with companies linked to China's military or intelligence, or those on America's restricted export list. Huang has also addressed concerns about DeepSeek's open-source R1 reasoning model, which was trained in China. While acknowledging the concerns, he stated there was no evidence that its origin alone presented dangers. He praised the R1 model as 'revolutionary' and noted its open-source nature empowers startups, new industries, and countries to participate in AI development. AI Masterclass for Students. Upskill Young Ones Today!– Join Now
